Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors
Aung Naing; Alain P. Algazi; Gerald S. Falchook; Ben Creelan; John D. Powderly; Seth Rosen; Minal Barve; Niharika B. Mettu · 2022 · Cancer
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract (excerpt)
BACKGROUND: Targeting programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO1) pathways is an appealing option for cancer treatment. METHODS: The open-label, phase 1/2 ECHO-203 study evaluated the safety, tolerability,…
Excerpt shown for reference under fair use — read the full paper at the publisher.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
Reproducible brain-wide association studies require thousands of individuals
Negative / Null Result ReportDaily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder
Negative / Null Result ReportEarly Brain Overgrowth in Autism Associated With an Increase in Cortical Surface Area Before Age 2 Years
Negative / Null Result ReportObjective evaluation of anosmia and ageusia in COVID‐19 patients: Single‐center experience on 72 cases
Negative / Null Result ReportPolarity and timing-dependent effects of transcranial direct current stimulation in explicit motor learning
Negative / Null Result ReportThe feedback-related negativity (FRN) revisited: New insights into the localization, meaning and network organization
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.1002/cncr.34512